PL2315580T3 - Formulacje farmaceutyczne oraz sposoby leczenia infekcji dróg oddechowych - Google Patents
Formulacje farmaceutyczne oraz sposoby leczenia infekcji dróg oddechowychInfo
- Publication number
- PL2315580T3 PL2315580T3 PL10711127T PL10711127T PL2315580T3 PL 2315580 T3 PL2315580 T3 PL 2315580T3 PL 10711127 T PL10711127 T PL 10711127T PL 10711127 T PL10711127 T PL 10711127T PL 2315580 T3 PL2315580 T3 PL 2315580T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- respiratory tract
- treating
- pharmaceutical formulations
- mole
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 206010057190 Respiratory tract infections Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000020029 respiratory tract infectious disease Diseases 0.000 title 1
- 208000019693 Lung disease Diseases 0.000 abstract 4
- 230000009798 acute exacerbation Effects 0.000 abstract 2
- 159000000007 calcium salts Chemical class 0.000 abstract 2
- 159000000000 sodium salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16376309P | 2009-03-26 | 2009-03-26 | |
| US16376709P | 2009-03-26 | 2009-03-26 | |
| US16377209P | 2009-03-26 | 2009-03-26 | |
| US25576409P | 2009-10-28 | 2009-10-28 | |
| US29809210P | 2010-01-25 | 2010-01-25 | |
| US30581910P | 2010-02-18 | 2010-02-18 | |
| EP10711127A EP2315580B1 (en) | 2009-03-26 | 2010-03-26 | Pharmaceutical formulations and methods for treating respiratory tract infections |
| PCT/US2010/028906 WO2010111644A1 (en) | 2009-03-26 | 2010-03-26 | Pharmaceutical formulations and methods for treating respiratory tract infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2315580T3 true PL2315580T3 (pl) | 2012-05-31 |
Family
ID=42562904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10711127T PL2315580T3 (pl) | 2009-03-26 | 2010-03-26 | Formulacje farmaceutyczne oraz sposoby leczenia infekcji dróg oddechowych |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20120107414A1 (pl) |
| EP (1) | EP2315580B1 (pl) |
| JP (1) | JP2012522011A (pl) |
| KR (1) | KR20120002981A (pl) |
| CN (1) | CN102448440A (pl) |
| AT (1) | ATE538774T1 (pl) |
| AU (1) | AU2010229724B2 (pl) |
| BR (1) | BRPI1014783A2 (pl) |
| CA (1) | CA2754680A1 (pl) |
| DK (1) | DK2315580T3 (pl) |
| ES (1) | ES2379775T3 (pl) |
| HR (1) | HRP20120262T1 (pl) |
| IL (1) | IL215275A0 (pl) |
| MX (1) | MX2011009959A (pl) |
| PL (1) | PL2315580T3 (pl) |
| PT (1) | PT2315580E (pl) |
| RS (1) | RS52239B (pl) |
| RU (1) | RU2011137961A (pl) |
| WO (1) | WO2010111644A1 (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2211956A4 (en) | 2007-10-10 | 2014-07-09 | Parion Sciences Inc | DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA |
| MX354829B (es) | 2009-03-26 | 2018-03-22 | Pulmatrix Operating Co Inc | Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares. |
| AU2010229730A1 (en) * | 2009-03-26 | 2011-10-06 | Pulmatrix, Inc. | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining |
| CA2809666C (en) | 2010-08-30 | 2020-09-22 | Michael M. Lipp | Dry powder formulations and methods for treating pulmonary diseases |
| EP2464346A1 (en) | 2010-08-30 | 2012-06-20 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| AU2011314007B2 (en) | 2010-09-29 | 2017-01-19 | Pulmatrix, Inc. | Cationic dry powders |
| RU2640921C2 (ru) | 2010-09-29 | 2018-01-12 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
| US8778383B2 (en) * | 2011-06-07 | 2014-07-15 | Parion Sciences, Inc. | Methods of treatment |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| WO2013052844A1 (en) | 2011-10-07 | 2013-04-11 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
| JP2015509788A (ja) | 2012-02-29 | 2015-04-02 | パルマトリックス，インコーポレイテッド | 吸入に適した乾燥粉末 |
| US9636360B2 (en) | 2012-09-18 | 2017-05-02 | pH Science Holdings, Inc | Method and composition for treating gastro-esophageal disorders |
| CA2907566C (en) | 2013-04-01 | 2023-08-22 | Pulmatrix, Inc. | Tiotropium dry powders |
| KR101658048B1 (ko) * | 2014-06-25 | 2016-09-20 | 한국생명공학연구원 | 포스파티딜콜린 합성경로 관여 물질을 포함하는 항바이러스용 조성물 |
| AU2015338717B2 (en) | 2014-10-31 | 2018-12-20 | Glaxosmithkline Intellectual Property Development Limited | Powder formulation |
| US10046007B2 (en) | 2015-06-24 | 2018-08-14 | Prescient Pharma, Llc | Compositions and methods for treatment of short telomere disorders |
| US11141545B2 (en) * | 2016-12-01 | 2021-10-12 | Mark L. Anderson, Llc | Sprayer technology |
| FR3081325B1 (fr) * | 2018-05-23 | 2020-10-09 | Univ Claude Bernard Lyon | Diltiazem pour son utilisation dans le traitement des infections microbiennes |
| EP3846825A4 (en) | 2018-09-05 | 2022-11-02 | Sensory Cloud, LLC | FORMULATIONS AND COMPOSITIONS FOR ORTHO- AND/OR RETRO-NASAL DELIVERY AND RELATED SYSTEMS, METHODS AND ARTICLES |
| US12018082B2 (en) * | 2019-09-16 | 2024-06-25 | The Regents Of The University Of California | Methods and agents for treating infections |
| IT202000005026A1 (it) * | 2020-03-09 | 2021-09-09 | Sofar Spa | Lattoferrina per uso inalatorio ad azione antivirale |
| WO2021245656A1 (en) * | 2020-05-31 | 2021-12-09 | Nicogen Ltd. | Nicotine compositions for inhalation and anti-viral uses thereof |
| CN113827614B (zh) * | 2020-06-24 | 2025-02-11 | 厦门大学 | 制备药用混合物的方法、所得药用混合物及其医药用途 |
| EP4192472A4 (en) * | 2020-08-10 | 2025-01-15 | Reverspah LLC | METHOD AND COMPOSITION FOR TREATING CORONAVIRUS, INFLUENZA AND ACUTE RESPIRATORY DISTRESS SYNDROME |
| CN111759851B (zh) * | 2020-08-17 | 2021-01-26 | 广东盛普生命科技有限公司 | 单宁酸在制备抗冠状病毒的药物方面的应用 |
| US20220280450A1 (en) * | 2021-03-05 | 2022-09-08 | Philera New Zealand Ltd. | Prevention and treatment of coronavirus and related respiratory infections |
| CN114410745B (zh) * | 2022-02-16 | 2023-05-02 | 长沙索科亚生物技术有限公司 | 粘性生物样本液化剂及其组合产品、试剂盒、扩增方法、检测方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4637815A (en) * | 1985-08-06 | 1987-01-20 | Lemole Gerald M | Irrigational hemostatic solution |
| JPH085779B2 (ja) * | 1989-09-22 | 1996-01-24 | 杏林製薬株式会社 | フレロキサシン点眼液 |
| US5466680A (en) * | 1992-03-26 | 1995-11-14 | Cytologics, Inc. | Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
| JP3414539B2 (ja) * | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| SK284948B6 (sk) * | 2000-04-06 | 2006-03-02 | Zentiva, A. S. | Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme |
| CN1194062C (zh) * | 2003-04-04 | 2005-03-23 | 王泽斌 | 一种融雪融冰组合物及其制备方法和应用 |
| US20050207983A1 (en) * | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| US20050281740A1 (en) * | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue |
| US20060073173A1 (en) * | 2004-10-04 | 2006-04-06 | Maria Banach | Large-scale manufacturing process for the production of pharmaceutical compositions |
| EP1906922A2 (en) * | 2005-05-18 | 2008-04-09 | Pulmatrix, Inc. | Formulations for alteration of biophysical properties of mucosal lining |
| EP2410985A2 (en) * | 2009-03-26 | 2012-02-01 | Pulmatrix, Inc. | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis |
| AU2010229730A1 (en) * | 2009-03-26 | 2011-10-06 | Pulmatrix, Inc. | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining |
-
2010
- 2010-03-26 MX MX2011009959A patent/MX2011009959A/es active IP Right Grant
- 2010-03-26 CN CN2010800232634A patent/CN102448440A/zh active Pending
- 2010-03-26 RS RS20120116A patent/RS52239B/sr unknown
- 2010-03-26 HR HR20120262T patent/HRP20120262T1/hr unknown
- 2010-03-26 JP JP2012502304A patent/JP2012522011A/ja active Pending
- 2010-03-26 DK DK10711127.0T patent/DK2315580T3/da active
- 2010-03-26 AT AT10711127T patent/ATE538774T1/de active
- 2010-03-26 PT PT10711127T patent/PT2315580E/pt unknown
- 2010-03-26 PL PL10711127T patent/PL2315580T3/pl unknown
- 2010-03-26 AU AU2010229724A patent/AU2010229724B2/en active Active
- 2010-03-26 US US13/259,651 patent/US20120107414A1/en not_active Abandoned
- 2010-03-26 KR KR1020117022477A patent/KR20120002981A/ko not_active Withdrawn
- 2010-03-26 CA CA2754680A patent/CA2754680A1/en not_active Abandoned
- 2010-03-26 RU RU2011137961/15A patent/RU2011137961A/ru unknown
- 2010-03-26 ES ES10711127T patent/ES2379775T3/es active Active
- 2010-03-26 WO PCT/US2010/028906 patent/WO2010111644A1/en not_active Ceased
- 2010-03-26 BR BRPI1014783A patent/BRPI1014783A2/pt not_active IP Right Cessation
- 2010-03-26 EP EP10711127A patent/EP2315580B1/en active Active
-
2011
- 2011-09-21 IL IL215275A patent/IL215275A0/en unknown
-
2013
- 2013-10-23 US US14/061,006 patent/US20140134251A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT2315580E (pt) | 2012-03-28 |
| AU2010229724A1 (en) | 2011-10-06 |
| EP2315580A1 (en) | 2011-05-04 |
| HRP20120262T1 (hr) | 2012-04-30 |
| EP2315580B1 (en) | 2011-12-28 |
| CA2754680A1 (en) | 2010-09-30 |
| DK2315580T3 (da) | 2012-04-10 |
| US20120107414A1 (en) | 2012-05-03 |
| RS52239B (sr) | 2012-10-31 |
| RU2011137961A (ru) | 2013-05-10 |
| US20140134251A1 (en) | 2014-05-15 |
| AU2010229724B2 (en) | 2014-07-17 |
| IL215275A0 (en) | 2011-11-30 |
| ATE538774T1 (de) | 2012-01-15 |
| JP2012522011A (ja) | 2012-09-20 |
| KR20120002981A (ko) | 2012-01-09 |
| HK1156847A1 (en) | 2012-06-22 |
| MX2011009959A (es) | 2012-01-27 |
| WO2010111644A1 (en) | 2010-09-30 |
| CN102448440A (zh) | 2012-05-09 |
| ES2379775T3 (es) | 2012-05-03 |
| BRPI1014783A2 (pt) | 2018-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL215275A0 (en) | Pharmaceutical formulations and methods for treating respiratory tract infections | |
| NZ609719A (en) | Pharmaceutical composition | |
| WO2010111650A3 (en) | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining | |
| CY1118059T1 (el) | Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων | |
| MY198204A (en) | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof | |
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
| WO2013003629A3 (en) | Methods and compositions for inhibition of bone resorption | |
| BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
| BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| EA201001781A1 (ru) | Применение гликозаминогликанов для перорального введения и композиции гликозаминогликанов | |
| NZ593475A (en) | Calcium salts for reducing exhalation of infectious bioaerosol particles | |
| MX2009006325A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
| EA200900095A1 (ru) | Лекарственные формы бифосфонатов для ингаляции и способы их применения | |
| TR201004464A2 (tr) | Kemik erimesi için formülasyon. | |
| MY148124A (en) | Preparation of a crystalline antibiotic substance | |
| UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
| GB0717442D0 (en) | Compositions and uses thereof | |
| NZ597657A (en) | Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections | |
| MX2008011321A (es) | Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual. | |
| UA111145C2 (uk) | Фармацевтична композиція | |
| TW200728281A (en) | Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions | |
| BRPI0512151A (pt) | solução concentrada de sal de sódio monoidratado do tenatoprazol, composição farmacêutica, utilização do sal de sódio monoidratado do tenatoprazol, processo de preparação do sal de sódio monoidratado do tenatoprazol, e composição para administração por via oral do sal de sódio monoidratado do tenatoprazol | |
| WO2009077485A3 (en) | 1(2)h-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents |